EconBiz - Find Economic Literature
    • Logout
    • Change account settings
  • A-Z
  • Beta
  • About EconBiz
  • News
  • Thesaurus (STW)
  • Academic Skills
  • Help
  •  My account 
    • Logout
    • Change account settings
  • Login
EconBiz - Find Economic Literature
Publications Events
Search options
Advanced Search history
My EconBiz
Favorites Loans Reservations Fines
    You are here:
  • Home
  • Search: person:"Noonan, Kevin"
Narrow search

Narrow search

Year of publication
Subject
All
Biotechnologie 1 Biotechnology 1 Experiment 1 Patent 1 Patent law 1 Patentrecht 1
Online availability
All
Free 1 Undetermined 1
Type of publication
All
Article 1 Book / Working Paper 1
Language
All
English 1 Undetermined 1
Author
All
Noonan, Kevin 2 Torrance, Andrew W. 1
Published in...
All
Antitrust Chronicle 1
Source
All
ECONIS (ZBW) 1 RePEc 1
Showing 1 - 2 of 2
Cover Image
Biotechnology Patent Law Top Ten of 2021 Experimentation, Blaze Marks, and Unspecified Ranges
Noonan, Kevin; Torrance, Andrew W. - 2023
Biotechnology has never demonstrated its benefits to society more than in 2021. The SARS-CoV-2 virus that caused the CoVID-19 pandemic met a formidable opponent in mRNA vaccines developed and supplied by Moderna and Pfizer/BioNTech. These vaccines are claimed in myriad – not Myriad – patents...
Persistent link: https://www.econbiz.de/10014255494
Saved in:
Cover Image
Federal Trade Commission Rejected in “Reverse Payment†Suit
Noonan, Kevin - In: Antitrust Chronicle 6 (2012)
This is where the FTC's reasoning begins to go astray, because courts have found generally that reverse payment arrangements reduce the delay in generic entry. Kevin E. Noonan (McDonnell Boehnen Hulbert & Berghoff)
Persistent link: https://www.econbiz.de/10010554726
Saved in:
A service of the
zbw
  • Sitemap
  • Plain language
  • Accessibility
  • Contact us
  • Imprint
  • Privacy

Loading...